Merck & Co., Inc. $MRK Stake Boosted by Renaissance Investment Group LLC

Renaissance Investment Group LLC raised its position in Merck & Co., Inc. (NYSE:MRK) by 184.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,877 shares of the company’s stock after purchasing an additional 14,840 shares during the quarter. Renaissance Investment Group LLC’s holdings in Merck & Co., Inc. were worth $3,324,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Curry Webb Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at $29,000. Horizons Wealth Management bought a new stake in Merck & Co., Inc. in the third quarter worth $30,000. Bullseye Investment Management LLC bought a new stake in Merck & Co., Inc. in the second quarter worth $27,000. Graney & King LLC boosted its holdings in Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares in the last quarter. Finally, Foresight Capital Management Advisors Inc. acquired a new position in Merck & Co., Inc. during the third quarter worth $43,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David Williams sold 52,847 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 228,238 shares of company stock worth $29,977,783 over the last ninety days. 0.17% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MRK. Wolfe Research raised their price objective on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research note on Tuesday, August 25th. Weiss Ratings raised shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Royal Bank Of Canada reduced their target price on Merck & Co., Inc. from $145.00 to $140.00 and set a “sector perform” rating for the company in a research report on Friday. Zacks Research downgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a report on Monday, October 19th. Finally, Cantor Fitzgerald lifted their target price on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Seventeen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $156.08.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $149.75 on Friday. The firm has a market capitalization of $369.46 billion, a P/E ratio of 154.38, a P/E/G ratio of 6.38 and a beta of 0.21. The stock has a fifty day moving average price of $146.90 and a two-hundred day moving average price of $126.69. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.40. The business had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.56%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.58 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 2.80 EPS for the current fiscal year.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.